The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1/2 dose escalation/expansion study of OR2805 alone or in combination in subjects with advanced solid tumors.
 
Anthony W. Tolcher
Employment - Next Oncology
Leadership - Next Oncology
Stock and Other Ownership Interests - Pyxis (Inst)
Consulting or Advisory Role - AbbVie (Inst); Aclaris Therapeutics (Inst); Adagene (Inst); Agenus (Inst); Aro Biotherapeutics (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Aximmune (Inst); Bayer (Inst); BioInvent (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo, Inc. (Inst); Deka Biosciences (Inst); Eleven Biotherapeutics (Inst); Elucida Oncology (Inst); EMD Serono (Inst); Gilde Healthcare (Inst); HBM Partners (Inst); HiberCell (Inst); IDEA Pharma (Inst); Ikena Oncology (Inst); Immuneering (Inst); Immunome (Inst); Immunomet (Inst); IMPAC Medical Systems (Inst); Janssen (Inst); Jazz Pharmaceuticals (Inst); Karma Oncology (Inst); Lengo Therapeutics (Inst); Lilly (Inst); Mekanistic Therapeutics (Inst); Menarini (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Nanobiotix (Inst); NBE Therapeutics (Inst); Ocellaris Pharma (Inst); Partner Therapeutics (Inst); Pelican Therapeutics (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Pierre Fabre (Inst); Pyxis (Inst); Ryvu Therapeutics (Inst); Seagen (Inst); Senti Biosciences (Inst); SK Life Sciences (Inst); Sotio (Inst); Spirea (Inst); Sunshine Guojian (Inst); Transcenta (Inst); Transgene (Inst); Trillium Therapeutics (Inst); Vincerx Pharma (Inst); Zentalis (Inst); ZielBio (Inst); Zymeworks (Inst)
Research Funding - AbbVie (Inst); ABL Bio (Inst); Adagene (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aminex (Inst); Amphivena (Inst); Apros Therapeutics (Inst); Arcellx (Inst); ARMO BioSciences (Inst); Arrys Therapeutics (Inst); Artios (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Astex Pharmaceuticals (Inst); Basilea (Inst); Bioinvent (Inst); Birdie (Inst); BJ Bioscience (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); CStone Pharmaceuticals (Inst); Daiichi Sankyo, Inc. (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); ImmuneOncia (Inst); Inhibrx (Inst); Innate Pharma (Inst); Janssen Research & Development (Inst); K-Group Beta (Inst); Kechow Pharma (Inst); Kiromic (Inst); Merck Sharp & Dohme (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Naturewise (Inst); NBE Therapeutics (Inst); NextCure (Inst); Nitto BioPharma (Inst); Odonate Therapeutics (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Qilu Puget Sound Biotherapeutics (Inst); Samumed (Inst); Seagen (Inst); Shanghai HaiHe Pharmaceutical (Inst); Spring Bank (Inst); Sunshine Guojian (Inst); Symphogen (Inst); Syndax (Inst); Synthorx (Inst); Takeda (Inst); Tizona Therapeutics, Inc. (Inst); Zymeworks (Inst)
Expert Testimony - Immunogen
Travel, Accommodations, Expenses - Sotio (Inst)
 
Andrae Lavon Vandross
No Relationships to Disclose
 
Justin C Moser
Honoraria - Caris Life Sciences
 
Michael S. Gordon
Stock and Other Ownership Interests - BeckonCall; Caremission; WCCT Global
Consulting or Advisory Role - Agenus; Castle Biosciences; Daiichi Sankyo; Deciphera; ImaginAb; Imaging Endpoints; Morphic Therapeutic; Neon Therapeutics; RedHill Biopharma; Salarius Pharmaceuticals; TRACON Pharma; Viracta Therapeutics
Research Funding - AADi (Inst); AADi (Inst); Abbvie (Inst); Acetylon Pharmaceuticals (Inst); Aduro Biotech (Inst); Advaxis (Inst); Agenus (Inst); Agenus (Inst); Alpine Immune Sciences (Inst); Amal Therapeutics (Inst); Amgen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Astellas Pharma (Inst); Athenex (Inst); Ayala Pharmaceuticals (Inst); Beigene (Inst); BeiGene (Inst); BioEclipse Therapeutics (Inst); BiolineRx (Inst); BiolineRx (Inst); BioNTech (Inst); BioNTech (Inst); BioXCel therapeutics (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Calithera Biosciences (Inst); CanBas (Inst); cantex (Inst); Caris Centers of Excellence (Inst); Celgene (Inst); Celldex (Inst); Codiak Biosciences (Inst); Corcept Therapeutics (Inst); Corcept Therapeutics (Inst); CytomX Therapeutics (Inst); Deciphera (Inst); Dracen (Inst); Driver Group (Inst); Elevation Oncology (Inst); Endocyte (Inst); ESSA (Inst); FibroGen (Inst); Five Prime Therapeutics (Inst); FORMA Therapeutics (Inst); Fujifilm (Inst); Fujifilm (Inst); Fujifilm (Inst); Fujifilm (Inst); Genentech/Roche (Inst); Genocea Biosciences (Inst); Genzada Pharmaceuticals (Inst); Genzada Pharmaceuticals (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Halozyme (Inst); Helix BioPharma (Inst); Helix BioPharma (Inst); Hengrui Therapeutics (Inst); IgM Biosciences (Inst); IgM Biosciences (Inst); ImaginAb (Inst); ImaginAb (Inst); ImmuneSensor Therapeutics (Inst); ImmuneSensor Therapeutics (Inst); Inanovate (Inst); Incyte (Inst); InhibRx (Inst); Inhibrx (Inst); Intra ImmuSG (Inst); Lilly (Inst); Lilly/ImClone (Inst); MabVax (Inst); MabVax (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Merck Serono (Inst); Merrimack (Inst); Millennium (Inst); Minneamrita Therapeutics (Inst); Molecular Partners (Inst); Nektar (Inst); Nektar (Inst); Nektar (Inst); Neon Therapeutics (Inst); Neon Therapeutics (Inst); Novartis (Inst); Novartis (Inst); Novita Pharmaceuticals (Inst); OncoMed (Inst); Pfizer (Inst); Pfizer (Inst); Phoenix Biotech (Inst); Pionyr (Inst); Plexxikon (Inst); Proderm IQ (Inst); Revolution Medicines (Inst); Revolution Medicines (Inst); Salarius Pharmaceuticals (Inst); Salarius Pharmaceuticals (Inst); Samumed (Inst); Seagen (Inst); Seattle Genetics/Astellas (Inst); Sirnaomics (Inst); Sirtex Medical (Inst); Strategia Therapeutics (Inst); Syndax (Inst); Syndax (Inst); SynDevRx (Inst); Syros Pharmaceuticals (Inst); tesaro (Inst); Tokai Pharmaceuticals (Inst); Tolero Pharmaceuticals (Inst); Tolero Pharmaceuticals (Inst); Toray Industries (Inst); TRACON Pharma (Inst); Trishula Therapeutics (Inst); Trovagene (Inst); TTC Oncology (Inst); TTC Oncology (Inst); Vedanta Biosciences (Inst); Verastem (Inst); Veru (Inst)
Patents, Royalties, Other Intellectual Property - Patient on patient selection for Clinical Trials
 
Katherine Harrop
Employment - OncoResponse; Seagen
Stock and Other Ownership Interests - OncoResponse; Seagen
 
Robert Lechleider
Employment - OncoResponse; Seagen
Leadership - OncoResponse
Stock and Other Ownership Interests - OncoResponse; Seagen